Melanoma

Daniel G. Coit, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson, Adil Daud, Raza A. Dilawari, Dominick DiMaio, Valerie Guild, Allan C. Halpern, F. Stephen Hodi, Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Anne Lind, Mary C. Martini, Anthony J. Olszanski, Scott K. Pruitt, Merrick I. RossSusan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, Marshall M. Urist

Research output: Contribution to journalReview articlepeer-review

57 Scopus citations

Abstract

These guidelines represent an effort to distill and simplify an enormous body of knowledge and experience into fairly simple management algorithms. In general, treatment recommendations for primary tumors are based on better data than those for treating recurrent disease. Few, if any, firm recommendations can be made about more controversial issues for patients with melanoma, such as the extent of workup or intensity of follow-up. These guidelines are intended as a point of departure, recognizing that all clinical decisions about individual patient management must be tempered by clinician judgment and other factors, such as local resources and expertise and the individual patient's needs, wishes, and expectations. Furthermore, these guidelines undergo annual revision and are continually updated as new data become available.

Original languageEnglish (US)
Pages (from-to)366-400
Number of pages35
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume10
Issue number3
DOIs
StatePublished - Mar 1 2012

Keywords

  • Adjuvant therapy
  • Biopsy
  • Chemotherapy
  • Interferon
  • Lymph node dissection
  • Margin
  • Melanoma
  • Metastases
  • NCCN clinical practice guidelines
  • NCCN guidelines
  • Pathology
  • Radiation therapy
  • Sentinel lymph node
  • Skin cancer
  • Surgical excision

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Melanoma'. Together they form a unique fingerprint.

Cite this